



Advanced Research of Targeting CDKs in Oncology

Guest Editor:

Dr. Sara Ravaioli

Biosciences Laboratory, IRCCS
Istituto Romagnolo per lo Studio
dei Tumori (IRST) “Dino
Amadori”, 47014 Meldola, Italy

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editor

Cyclin-dependent kinases (CDKs) are cell cycle key regulators overexpressed and deemed as therapeutic targets in many cancer types. CDK proteins lead to G1/S progression through phosphorylation of Rb facilitating tumorigenesis. The first clinically approved CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) have uncovered the great importance of targeting this pathway, demonstrating efficacy, but the identification of predictive biomarkers and the mechanisms underlying drug resistance still represent major unmet clinical needs. Moreover, new therapeutic approaches of combination therapy are emerging as a hot topic in this context to overcome resistance and should be explored. This Special Issue welcomes both basic studies and translational research including original articles, short communications, reviews, and commentaries, focused on anticancer strategies against CDKs. Special attention will be given to manuscripts reporting the molecular mechanisms of drug resistance, predictive biomarkers, and new therapeutic approaches in targeting CDK pathway in cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI